Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Equity Brief: Ratings Changes for December 3rd: HMA, IGT, INTC, ITUB, JNS, KNXA, LULU, MYGN


Print article Print article
Copyright © Thomson Reuters 2012. All rights reserved.
2012-12-03 16:16:00 -

A number of stocks were upgraded and downgraded by equities research analysts
today, as reported by Analyst Ratings Network ( bit.ly/equitybriefdaily)
and Equity Brief:

CRT Capital downgraded shares of Health Management Associates (HMA) from a fair
value rating to a sell rating. Their analysts now have a $6.50 price target on
the stock.

Deutsche Bank upgraded shares of International Game Technology (IGT) from a hold
rating to a buy rating. Deutsche Bank now has a $19.00 price target on the
stock, up previously from $16.00.

Sterne Agee lowered its price target on shares of Intel (INTC) from $19.00 to
$18.00. They have a neutral rating on the stock.

Credit Suisse upgraded shares of Itau Unibanco Holding Sociedade Anonima (ITUB)
from an underperform rating to a neutral rating.

Goldman Sachs downgraded shares of Janus 
Capital Group Inc. (JNS) from a neutral rating to a sell rating. Their analysts now have a $7.00 price target on the stock, down previously from $8.00. They wrote, "We expect JNS shares to underperform given: (1) Soft relative equity fund performance and tougher INTECH performance comparisons suggest more outflows; (2) pressure on revenues and op. margin from negative performance fees; and (3) we see multiple compression as investors refocus on soft fundamentals as technical tailwind from Dai-ichi's purchase of a 20% stake rolls off. We lower our 2012/2013/2014 EPS estimates to $0.56/$0.53/$0.60 from $0.56/$0.60/$0.71 on modest flow/margin expectations, 9-15% below consensus." JMP Securities downgraded shares of Kenexa Co. (KNXA) from an outperform rating to a market perform rating. Canaccord Genuity initiated coverage on shares of Lululemon (LULU). They issued a buy rating on the stock and set a $91.00 price target. They wrote, "We are initiating coverage of LULU with a BUY rating and $91 price target. We believe LULU is evolving from an athletic brand with its roots in yoga to a lifestyle brand that is marrying form and function. To that end, the company has had issues in keeping pace with demand. Our supply chain checks suggest capacity in 2013 will expand and as a result traffic and conversion should improve, resulting in a reacceleration of comp growth." Mizuho downgraded shares of Myriad Genetics (MYGN) from a buy rating to a neutral rating. Their analysts now have a $30.00 price target on the stock, down previously from $31.00. Goldman Sachs downgraded shares of Myriad Genetics (MYGN) from a buy rating to a neutral rating. Barclays Capital upgraded shares of Nisource (NI) from an equal weight rating to an overweight rating. Barclays Capital now has a $27.00 price target on the stock, up previously from $26.00. Stay on top of analysts' coverage with Analyst Ratings Network's free daily email newsletter that provides a concise list of analysts' upgrades, downgrades and initiations. Register at bit.ly/equitybriefdaily Content and Media Contact: newseditor@equitybrief.net This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Equity Brief via Thomson Reuters ONE [HUG#1662116]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com